Similar articles for PMID: 32358042

1

Cite

Share

Combined ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option.

Adnan A, Basu S. Adnan A, et al. J Nucl Med Technol. 2020 Sep;48(3):292-294. doi: 10.2967/jnmt.119.237354. Epub 2020 May 1. J Nucl Med Technol. 2020. PMID: 32358042 Review.

Cite

Share

2

Cite

Share

Prevalence of hitherto unknown brain meningioma detected on ⁶⁸Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors.

Parghane RV, Talole S, Basu S. Parghane RV, et al. World J Nucl Med. 2019 Apr-Jun;18(2):160-170. doi: 10.4103/wjnm.WJNM_39_18. World J Nucl Med. 2019. PMID: 31040748 Free PMC article.

Cite

Share

3

Cite

Share

MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with ⁶⁸Ga-DOTATATE and ¹⁸F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.

Sampathirao N, Basu S. Sampathirao N, et al. J Nucl Med Technol. 2017 Mar;45(1):34-41. doi: 10.2967/jnmt.116.185777. Epub 2017 Feb 2. J Nucl Med Technol. 2017. PMID: 28154019 Free article.

Cite

Share

4

Cite

Share

Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.

Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215

Cite

Share

5

Cite

Share

Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.

Jois B, Asopa R, Basu S. Jois B, et al. Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429. Clin Nucl Med. 2014. PMID: 24662668

Cite

Share

6

Cite

Share

Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?

Zemczak A, Kołodziej M, Gut P, Królicki L, Kos-Kudła B, Kamiński G, Ruchała M, Pawlak D, Kunikowska J. Zemczak A, et al. Endokrynol Pol. 2020;71(3):240-248. doi: 10.5603/EP.a2020.0014. Epub 2020 Apr 15. Endokrynol Pol. 2020. PMID: 32293704 Free article.

Cite

Share

7

Cite

Share

Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.

Parghane RV, Talole S, Prabhash K, Basu S. Parghane RV, et al. Clin Nucl Med. 2017 Jun;42(6):428-435. doi: 10.1097/RLU.0000000000001639. Clin Nucl Med. 2017. PMID: 28319500

Cite

Share

8

Cite

Share

Clinical utility of ¹⁷⁷ Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity.

Parghane RV, Naik C, Talole S, Desmukh A, Chaukar D, Banerjee S, Basu S. Parghane RV, et al. Head Neck. 2020 Mar;42(3):401-416. doi: 10.1002/hed.26024. Epub 2019 Nov 22. Head Neck. 2020. PMID: 31755622

Cite

Share

9

Cite

Share

Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (⁶⁸Ga-DOTATATE and ¹⁸F-fluorodeoxyglucose) molecular imaging and disease stabilization following ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy.

Jadhav S, Basu S. Jadhav S, et al. World J Nucl Med. 2019 Dec 18;18(4):431-433. doi: 10.4103/wjnm.WJNM_76_18. eCollection 2019 Oct-Dec. World J Nucl Med. 2019. PMID: 31933564 Free PMC article.

Cite

Share

10

Cite

Share

Clinical efficacy of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A "not-so-promising" result compared to GEP-NETs.

Basu S, Parghane RV, Naik C. Basu S, et al. World J Nucl Med. 2020 Jul 1;19(3):205-210. doi: 10.4103/wjnm.WJNM_21_19. eCollection 2020 Jul-Sep. World J Nucl Med. 2020. PMID: 33354174 Free PMC article.

Cite

Share